{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:25:29Z","timestamp":1793111129371,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Evidence for the treatment of patients with mild-to-moderate chronic obstructive pulmonary disease (COPD) is limited. The efficacy of N-acetylcysteine (an antioxidant and mucolytic agent) for patients with mild-to-moderate COPD is uncertain. In this multicentre, randomised, double-blind, placebo-controlled trial, we randomly assigned 968 patients with mild-to-moderate COPD to treatment with N-acetylcysteine (600\u2009mg, twice daily) or matched placebo for two years. Eligible participants were 40-80 years of age and had mild-to-moderate COPD (forced expiratory volume in 1\u2009second [FEV\n                    <jats:sub>1<\/jats:sub>\n                    ] to forced vital capacity ratio &lt;0.70 and an FEV\n                    <jats:sub>1<\/jats:sub>\n                    \u2009\u2265\u200950% predicted value after bronchodilator use). The coprimary outcomes were the annual rate of total exacerbations and the between-group difference in the change from baseline to 24 months in FEV\n                    <jats:sub>1<\/jats:sub>\n                    before bronchodilator use. COPD exacerbation was defined as the appearance or worsening of at least two major symptoms (cough, expectoration, purulent sputum, wheezing, or dyspnoea) persisting for at least 48\u2009hours. Assessment of exacerbations was conducted every three months, and lung function was performed annually after enrolment. The difference between the N-acetylcysteine group and the placebo group in the annual rate of total exacerbation were not significant (0.65 vs. 0.72 per patient-year; relative risk [RR], 0.90; 95% confidence interval [CI], 0.80\u20131.02;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.10). There was no significant difference in FEV\n                    <jats:sub>1<\/jats:sub>\n                    before bronchodilator use at 24 months. Long-term treatment with high-dose N-acetylcysteine neither significantly reduced the annual rate of total exacerbations nor improved lung function in patients with mild-to-moderate COPD. Chinese Clinical Trial Registration: ChiCTR-IIR-17012604.\n                  <\/jats:p>","DOI":"10.1038\/s41467-024-51079-1","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T12:02:38Z","timestamp":1727697758000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Effect of high-dose N-acetylcysteine on exacerbations and lung function in patients with mild-to-moderate COPD: a double-blind, parallel group, multicentre randomised clinical trial"],"prefix":"10.1038","volume":"15","author":[{"given":"Yumin","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0720-4674","authenticated-orcid":false,"given":"Fan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenglei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zanfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyun","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongliang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heshen","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijian","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghua","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhishan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1394-0360","authenticated-orcid":false,"given":"Peiyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangwen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguang","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanshan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6651-634X","authenticated-orcid":false,"given":"Pixin","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of China N-acetylcysteine in Mild-to-moderate COPD Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuxiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longhui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suizheng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueding","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfei","family":"Bin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingshan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"51079_CR1","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S2213-2600(21)00511-7","volume":"10","author":"D Adeloye","year":"2022","unstructured":"Adeloye, D. et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir. Med. 10, 447\u2013458 (2022).","journal-title":"Lancet Respir. Med."},{"key":"51079_CR2","doi-asserted-by":"publisher","first-page":"e069679","DOI":"10.1136\/bmj-2021-069679","volume":"378","author":"S Safiri","year":"2022","unstructured":"Safiri, S. et al. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019. BMJ 378, e069679 (2022).","journal-title":"BMJ"},{"key":"51079_CR3","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1164\/rccm.200612-1749OC","volume":"176","author":"N Zhong","year":"2007","unstructured":"Zhong, N. et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am. J. Respir. Crit. Care. Med. 176, 753\u2013760 (2007).","journal-title":"Am. J. Respir. Crit. Care. Med."},{"key":"51079_CR4","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/S0140-6736(18)30841-9","volume":"391","author":"C Wang","year":"2018","unstructured":"Wang, C. et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet 391, 1706\u20131717 (2018).","journal-title":"Lancet"},{"key":"51079_CR5","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1164\/rccm.201511-2219OC","volume":"194","author":"SP Bhatt","year":"2016","unstructured":"Bhatt, S. P. et al. Association between Functional Small Airway Disease and FEV1 Decline in Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care. Med. 194, 178\u2013184 (2016).","journal-title":"Am. J. Respir. Crit. Care. Med."},{"key":"51079_CR6","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1505971","volume":"374","author":"PG Woodruff","year":"2016","unstructured":"Woodruff, P. G. et al. Clinical significance of symptoms in smokers with preserved pulmonary function. N. Engl. J. Med. 374, 1811\u20131821 (2016).","journal-title":"N. Engl. J. Med."},{"key":"51079_CR7","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0140-6736(09)61298-8","volume":"374","author":"M Decramer","year":"2009","unstructured":"Decramer, M. et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 374, 1171\u20131178 (2009).","journal-title":"Lancet"},{"key":"51079_CR8","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1164\/rccm.201605-1014OC","volume":"195","author":"MT Dransfield","year":"2017","unstructured":"Dransfield, M. T. et al. Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care. Med. 195, 324\u2013330 (2017).","journal-title":"Am. J. Respir. Crit. Care. Med."},{"key":"51079_CR9","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1056\/NEJMoa1700228","volume":"377","author":"Y Zhou","year":"2017","unstructured":"Zhou, Y. et al. Tiotropium in early-stage chronic obstructive pulmonary disease. N. Engl. J. Med. 377, 923\u2013935 (2017).","journal-title":"N. Engl. J. Med."},{"key":"51079_CR10","doi-asserted-by":"publisher","first-page":"2300239","DOI":"10.1183\/13993003.00239-2023","volume":"61","author":"A Agust\u00ed","year":"2023","unstructured":"Agust\u00ed, A. et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Eur. Respir. J. 61, 2300239 (2023).","journal-title":"Eur. Respir. J."},{"key":"51079_CR11","first-page":"135","volume":"56","author":"FJ van Overveld","year":"2005","unstructured":"van Overveld, F. J. et al. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine. J. Physiol. Pharmacol. 56, 135\u2013142 (2005).","journal-title":"J. Physiol. Pharmacol."},{"key":"51079_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1586\/17476348.2016.1121105","volume":"10","author":"MG Matera","year":"2016","unstructured":"Matera, M. G. et al. Oxidation pathway and exacerbations in COPD: the role of NAC. Expert. Rev. Respir. Med. 10, 89\u201397 (2016).","journal-title":"Expert. Rev. Respir. Med."},{"key":"51079_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12931-016-0500-y","volume":"18","author":"M Cazzola","year":"2017","unstructured":"Cazzola, M. et al. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. Respir. Res. 18, 26 (2017).","journal-title":"Respir. Res."},{"key":"51079_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S2213-2600(13)70286-8","volume":"2","author":"JP Zheng","year":"2014","unstructured":"Zheng, J. P. et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir. Med. 2, 187\u2013194 (2014).","journal-title":"Lancet Respir. Med."},{"key":"51079_CR15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1378\/chest.12-2357","volume":"144","author":"HN Tse","year":"2013","unstructured":"Tse, H. N. et al. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest 144, 106\u2013118 (2013).","journal-title":"Chest"},{"key":"51079_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.pupt.2005.12.007","volume":"20","author":"AM Sadowska","year":"2007","unstructured":"Sadowska, A. M. et al. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. Pulm. Pharmacol. Ther. 20, 9\u201322 (2007).","journal-title":"Pulm. Pharmacol. Ther."},{"key":"51079_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40264-020-01026-y","volume":"44","author":"P Calverley","year":"2021","unstructured":"Calverley, P. et al. Safety of N-acetylcysteine at high doses in chronic respiratory diseases: a review. Drug. Saf. 44, 273\u2013290 (2021).","journal-title":"Drug. Saf."},{"key":"51079_CR18","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1164\/rccm.201710-2028PP","volume":"197","author":"FJ Martinez","year":"2018","unstructured":"Martinez, F. J. et al. At the root: defining and halting progression of early chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care. Med. 197, 1540\u20131551 (2018).","journal-title":"Am. J. Respir. Crit. Care. Med."},{"key":"51079_CR19","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/S0140-6736(05)66456-2","volume":"365","author":"M Decramer","year":"2005","unstructured":"Decramer, M. et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 365, 1552\u20131560 (2005).","journal-title":"Lancet"},{"key":"51079_CR20","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1159\/000029447","volume":"66","author":"R Pela","year":"1999","unstructured":"Pela, R. et al. N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration 66, 495\u2013500 (1999).","journal-title":"Respiration"},{"key":"51079_CR21","first-page":"CD001287","volume":"5","author":"P Poole","year":"2019","unstructured":"Poole, P. et al. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane. Database. Syst. Rev. 5, CD001287 (2019).","journal-title":"Cochrane. Database. Syst. Rev."},{"key":"51079_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1164\/rccm.202009-3533SO","volume":"203","author":"DMG Halpin","year":"2021","unstructured":"Halpin, D. M. G. et al. Global initiative for the diagnosis, management, and prevention of chronic obstructive lung disease. The 2020 GOLD Science Committee Report on COVID-19 and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care. Med. 203, 24\u201336 (2021).","journal-title":"Am. J. Respir. Crit. Care. Med."},{"key":"51079_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02000-w","volume":"19","author":"MA Alsallakh","year":"2021","unstructured":"Alsallakh, M. A. et al. Impact of COVID-19 lockdown on the incidence and mortality of acute exacerbations of chronic obstructive pulmonary disease: national interrupted time series analyses for Scotland and Wales. BMC. Med. 19, 124 (2021).","journal-title":"BMC. Med."},{"key":"51079_CR24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/medicina58010066","volume":"58","author":"M Lawless","year":"2022","unstructured":"Lawless, M. et al. Impact of COVID-19 on hospital admissions for COPD exacerbation: lessons for future care. Medicina (Kaunas) 58, 66 (2022).","journal-title":"Medicina (Kaunas)"},{"key":"51079_CR25","doi-asserted-by":"publisher","first-page":"1700711","DOI":"10.1183\/13993003.00711-2017","volume":"50","author":"RW Dal Negro","year":"2017","unstructured":"Dal Negro, R. W. et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur. Respir. J. 50, 1700711 (2017).","journal-title":"Eur. Respir. J."},{"key":"51079_CR26","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1164\/rccm.202008-3328PP","volume":"203","author":"MK Han","year":"2021","unstructured":"Han, M. K. et al. From GOLD 0 to Pre-COPD. Am. J. Respir. Crit. Care. Med. 203, 414\u2013423 (2021).","journal-title":"Am. J. Respir. Crit. Care. Med."},{"key":"51079_CR27","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1164\/rccm.202107-1663SO","volume":"205","author":"FJ Martinez","year":"2022","unstructured":"Martinez, F. J. et al. Treatment trials in young patients with chronic obstructive pulmonary disease and pre-chronic obstructive pulmonary disease patients: time to move forward. Am. J. Respir. Crit. Care. Med. 205, 275\u2013287 (2022).","journal-title":"Am. J. Respir. Crit. Care. Med."},{"key":"51079_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04701-8","volume":"21","author":"H Tian","year":"2020","unstructured":"Tian, H. et al. High-dose N-acetylcysteine for long-term, regular treatment of early-stage chronic obstructive pulmonary disease (GOLD I-II): study protocol for a multicenter, double-blinded, parallel-group, randomized controlled trial in China. Trials 21, 780 (2020).","journal-title":"Trials"},{"key":"51079_CR29","doi-asserted-by":"publisher","first-page":"196","DOI":"10.7326\/0003-4819-106-2-196","volume":"106","author":"NR Anthonisen","year":"1987","unstructured":"Anthonisen, N. R. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 106, 196\u2013204 (1987).","journal-title":"Ann. Intern. Med."},{"key":"51079_CR30","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","volume":"359","author":"DP Tashkin","year":"2008","unstructured":"Tashkin, D. P. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 359, 1543\u20131554 (2008).","journal-title":"N. Engl. J. Med."},{"key":"51079_CR31","first-page":"1662","volume":"2","author":"CM Fletcher","year":"1960","unstructured":"Fletcher, C. M. Standardised questionnaire on respiratory symptoms: a statement prepared and approved by the MRC Committee on the Aetiology of Chronic Bronchitis (MRC breathlessness score). BMJ 2, 1662 (1960).","journal-title":"BMJ"},{"key":"51079_CR32","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1183\/09031936.00102509","volume":"34","author":"PW Jones","year":"2009","unstructured":"Jones, P. W. et al. Development and first validation of the COPD assessment test. Eur. Respir. J. 34, 648\u2013654 (2009).","journal-title":"Eur. Respir. J."},{"key":"51079_CR33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1183\/09031936.05.00034805","volume":"26","author":"MR Miller","year":"2005","unstructured":"Miller, M. R. et al. Standardisation of spirometry. Eur. Respir. J 26, 319\u2013338 (2005).","journal-title":"Eur. Respir. J"},{"key":"51079_CR34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1183\/09031936.05.00034505","volume":"226","author":"MR Miller","year":"2005","unstructured":"Miller, M. R. et al. General considerations for lung function testing. Eur. Respir. J. 226, 153\u2013161 (2005).","journal-title":"Eur. Respir. J."},{"key":"51079_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1183\/09041950.005s1693","volume":"16","author":"PH Quanjer","year":"1993","unstructured":"Quanjer, P. H. et al. Lung volumes and forced ventilatory flows: Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal: Official Statement of the European Respiratory Society. Eur. Respir. J. Suppl. 16, 5\u201340 (1993).","journal-title":"Eur. Respir. J. Suppl."},{"key":"51079_CR36","first-page":"50","volume":"115","author":"J Zheng","year":"2002","unstructured":"Zheng, J. & Zhong, N. Normative values of pulmonary function testing in Chinese adults. Chin. Med. J. (Engl) 115, 50\u201354 (2002).","journal-title":"Chin. Med. J. (Engl)"},{"key":"51079_CR37","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1164\/rccm.202303-0400SO","volume":"208","author":"M Cazzola","year":"2023","unstructured":"Cazzola, M. et al. An update on outcomes for COPD pharmacological trials: A COPD investigators report\u2014Reassessment of the 2008 American Thoracic Society\/European Respiratory Society Statement on Outcomes for COPD Pharmacological Trials. Am. J. Respir. Crit. Care. Med. 208, 374\u2013394 (2023).","journal-title":"Am. J. Respir. Crit. Care. Med."},{"key":"51079_CR38","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1164\/rccm.200508-1338PP","volume":"173","author":"S Suissa","year":"2006","unstructured":"Suissa, S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care. Med. 173, 842\u2013846 (2006).","journal-title":"Am. J. Respir. Crit. Care. Med."},{"key":"51079_CR39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1183\/09031936.00161507","volume":"32","author":"ON Keene","year":"2008","unstructured":"Keene, O. N. et al. Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited. Eur. Respir. J. 32, 17\u201324 (2008).","journal-title":"Eur. Respir. J."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51079-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51079-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51079-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T12:03:49Z","timestamp":1727697829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51079-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51079"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-51079-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3363930\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"assertion":[{"value":"24 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This trial was approved by the ethics committee at each hospital according to the requirements of Chinese clinical trial guidelines. All patients provided written informed consent before enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"8468"}}